Manuscripts
Showing 1543 manuscripts.
Metabolic effects of initiating lopinavir/ritonavir-based regimens among young children.
Citation
K Angelidou, G Aldrovandi, P Palumbo, IMPAACT P1060 Study team, K Patel, J Lindsey. Metabolic effects of initiating lopinavir/ritonavir-based regimens among young children.. AIDS. 2018. 32: 2327-2336. PMID: 30102656Year
2018
Journal
AIDS
Study
P1060
Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood
Citation
Brookie M Best, Jorge Pinto, Ellen G Chadwick, Eric S Daar, Peter L Havens, Natella Rakhmanina, Edmund V Capparelli, Jincheng Yang, Mina Nikanjam. Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood. Journal of Clinical Pharmacology. 2018. 58: 1604-1617. PMID: 30252146Year
2018
Journal
Journal of Clinical Pharmacology
Study
P1083, P1030, P1038
Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children.
Citation
Moscicki AB, Saah A, Levin MJ, IMPAACT P1085 Protocol Team, Weinberg A, Huang S. Persistence of memory B-cell and T-cell responses to the quadrivalent HPV vaccine in HIV-infected children.. AIDS. 2018. 32: 851-860. PMID: 29424778Year
2018
Journal
AIDS
Study
P1085
Quantification of variation and the impact of biomass in targeted 16S rRNA gene sequencing studies.
Citation
H Adisetivo, D Lee, S Zabih, L Hung, TA Wiklinson, PS Pannaraj, RC She, JD Bard, NH Tobin, GM Aldrovandi, JM Bender, F Li. Quantification of variation and the impact of biomass in targeted 16S rRNA gene sequencing studies.. Microbiome. 2018. 6: 155. PMID: 30201048Year
2018
Journal
Microbiome
Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations.
Citation
KA Lee-Sarwar, HM Tun, BP Brown, PS Pannaraj, JM Bender, MB Azad, AL Thompson, ST Weiss, MA Azcarate-Peril, AA Litonjua, AL Kozyrskyi, HB Jaspan, GM Aldrovandi, L Kuhn, NT Ho, F Li. Meta-analysis of effects of exclusive breastfeeding on infant gut microbiota across populations.. Nature Communications. 2018. 9: 4169. PMID: 30301893Year
2018
Journal
Nature Communications
Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.
Citation
B Homony, H Teppler, AJ Rodgers, BL Graham, T Fenton, LM Frenkel, RS Browning, R Hazra, AA Wiznia, IMPAACT 1066 Study Team, S Nachman, C Alvero. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.. Lancet HIV. 2018. 5: e715-e722. PMID: 30527329Year
2018
Journal
Lancet HIV
Study
P1066
Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial
Citation
Sean S Brummel, James A McIntyre, Friday Saidi, Karin L Kingman, Avy Violari, Nahida Chakhtoura, Dingase Dula, David E Shapiro, Vidya Mave, Mary Glenn Fowler, Lee Fairlie, Judith S Currier, Gerhard Theron, Moreen Kamateeka, Tsungai Chipato, Benjamin H Chi, Lynda Stranix-Chibanda, Teacler Nematadzira, Dhayendre Moodley, Debika Bhattacharya, Risa M Hoffman, Amita Gupta, Konstantia Nadia Angelidou, Anne Coletti, IMPAACT PROMISE 1077BF/FF Team. Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial. HIV Clinical Trials. 2018. 19: 209-224. PMID: 30890061Year
2018
Journal
HIV Clinical Trials
Study
1077BF, 1077FF
Defining Study Outcomes That Better Reflect Individual Response to Treatment
Citation
Konstantia Angelidou, Jane Lindsey, Avy Violary, Moderndran Archary, Linda Barlow, Brian Claggett, Michael Hughes, Lee-Jen Wei, IMPAACT P1060 Study Team, Paul Palumbo. Defining Study Outcomes That Better Reflect Individual Response to Treatment. Pediatric Infectious Disease Journal. 2018. 37: 258-262. PMID: 29189677Year
2018
Journal
Pediatric Infectious Disease Journal
Study
P1060
A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women
Citation
Angela C Colbers, Alwin D R Huitema, Paolo Denti, Kelly E Dooley, Edmund Capparelli, Brookie M Best, Tim R Cressey, Rick Greupink, Frans G M Russel, Mark Mirochnick, David M Burger, Stein Schalkwijk, Rob Ter Heine. A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women. Clinical Pharmacokinetics. 2018. 57: 1421-1433. PMID: 29520730Year
2018
Journal
Clinical Pharmacokinetics
Study
P1026S
H1N1 influenza vaccination in HIV-infected women on effective antiretroviral treatment does not appear to impact HIV-1 DNA genotypes or concentration
Citation
Christen E. Salyer, Kelly M. Richardson, Adriana Weinberg, Sharon Nachman, Lisa M. Frenkel, Thor A. Wagner, Hannah C. Huang. H1N1 influenza vaccination in HIV-infected women on effective antiretroviral treatment does not appear to impact HIV-1 DNA genotypes or concentration. Journal of Acquired Immune Deficiency Syndromes. 2017. 14: 7. PMID: 28193244Year
2017
Journal
Journal of Acquired Immune Deficiency Syndromes
Study
P1086